10-Q: Profusa Reports Q3 Losses, Nasdaq Delisting Risk, and Bitcoin Strategy

Profusa, Inc. reported significant net losses and negative operating cash flows for Q3 2025, raising substantial doubt about its going concern ability while facing Nasdaq delisting notices and expanding its Bitcoin treasury strategy.

Summary

• Net loss for the three months ended September 30, 2025, was $(22.2) million, a significant increase from $(2.5) million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $(27.3) million, compared to $(7.0) million for the same period in 2024.
• Used $(11.1) million in cash from operating activities for the nine months ended September 30, 2025.
• Working capital deficit of approximately $(19.3) million as of September 30, 2025.
• Received Nasdaq notices for failing to meet minimum Market Value of Listed Securities ($50 million) and minimum bid price ($1.00 per share) requirements, with compliance periods until March 10, 2026.
• Completed a business combination with NorthView Acquisition Corporation on July 11, 2025, resulting in a reverse recapitalization.
• Implemented a Bitcoin treasury strategy, purchasing $1.0 million (8.53 coins) as of September 30, 2025, and an additional $1.0 million (7.98 coins) in October 2025.
• Secured a Committed Equity Facility (ELOC) with Ascent for up to $100 million, having drawn approximately $3.5 million as of September 30, 2025, and an additional $3.8 million in October 2025.
• Identified material weaknesses in internal control over financial reporting, including segregation of duties, lack of review controls for financial instrument valuations, and lack of technical accounting expertise.
• Management believes current liquidity is not sufficient to alleviate substantial doubt about the Company's ability to continue as a going concern within one year.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position, marked by rapidly escalating net losses, negative operating cash flow, and an explicit "going concern" warning from management. The Nasdaq delisting notices for both market value and bid price indicate severe market underperformance and a high risk of losing its exchange listing, which would significantly impair liquidity and investor confidence. While the business combination and ELOC provide some capital, the magnitude of losses and the working capital deficit suggest these funds may be insufficient to achieve sustainable operations. The adoption of a Bitcoin treasury strategy introduces an additional layer of extreme volatility and risk, which is highly unusual for a clinical-stage medical technology company and further complicates its financial outlook. Material weaknesses in internal controls also raise concerns about financial reporting reliability. Given these overwhelming negative factors and the high probability of further value erosion, a strong sell recommendation is warranted.

Positives

• Successful completion of the business combination with NorthView Acquisition Corporation on July 11, 2025.
• Secured a Committed Equity Facility (ELOC) for up to $100 million, providing a potential source of future funding.
• Proceeds from financing activities increased significantly to $14.9 million for the nine months ended September 30, 2025, compared to $1.8 million in the prior year.
• Cash balance increased to $3.0 million as of September 30, 2025, from $0.2 million at December 31, 2024.
• Lumee Oxygen Platform has received regulatory approval (CE mark) in Europe, with commercialization targeted for early 2026.
• Active research and development on Lumee Glucose Platform, a continuous glucose monitor, with a European launch expected in 2025 subject to regulatory approval.
• Strategic Bitcoin treasury strategy implemented, with $2.0 million invested in Bitcoin as of the filing date.

Negatives

• Significant net loss of $(22.2) million for Q3 2025, a substantial increase from $(2.5) million in Q3 2024.
• Accumulated deficit increased to $(152.2) million as of September 30, 2025, from $(124.9) million at December 31, 2024.
• Working capital deficit of approximately $(19.3) million as of September 30, 2025.
• Substantial doubt about the Company's ability to continue as a going concern within one year.
• Received Nasdaq delisting notices for failing to meet minimum Market Value of Listed Securities ($50 million) and minimum bid price ($1.00 per share) requirements.
• General and administrative expenses increased by 2636% to $20.987 million in Q3 2025, primarily due to $15.219 million in transaction costs related to the business combination.
• Research and development expenses increased by 76% to $722 thousand in Q3 2025.
• No government grant revenue recognized in 2025, compared to $75 thousand in Q3 2024.
• PPP Loan 2 is in default due to non-payment, with an outstanding balance of $1.386 million.
• Promissory notes are in default, with an outstanding balance of $1.045 million.
• Loss on change in fair value of digital assets of $(28) thousand for Q3 2025.
• Financing costs of $(1.443) million incurred in Q3 2025 related to the ELOC agreement.

Risks

• Ability to obtain future financing.
• Advances and trends in new technologies and industry standards.
• Results of clinical trials.
• Regulatory approval and market acceptance of products (FDA, international agencies).
• Development of sales channels.
• Certain strategic relationships.
• Litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors.
• Ability to attract and retain employees necessary to support growth.
• High volatility of Bitcoin, which does not pay interest or dividends.
• Bitcoin holdings may significantly impact financial results and stock price.
• Bitcoin treasury strategy has not been tested over an extended period or different market conditions.
• Counterparty risks related to Bitcoin custodians, including potential loss in case of custodian bankruptcy.
• Broader digital assets industry subject to counterparty risks, potentially impacting Bitcoin adoption and price.
• Changes in ownership of Bitcoin could have accounting, regulatory, and other impacts, including increased volatility in financial results due to fair value accounting.
• Fluctuations in Bitcoin price are likely to influence financial results and stock price.
• Bitcoin and other digital assets are novel and subject to significant legal, commercial, regulatory, and technical uncertainty.
• Regulatory change reclassifying Bitcoin as a security could lead to classification as an investment company under the 1940 Act.
• Risk of non-performance by counterparties in Bitcoin treasury strategy.
• Security breaches or cyberattacks leading to loss of Bitcoin or private keys.
• Concentration of Bitcoin holdings enhances inherent risks.
• Emergence or growth of other digital assets (e.g., stablecoins, CBDCs) could negatively impact Bitcoin price.
• Bitcoin holdings are less liquid than cash and cash equivalents.
• Temporary or permanent blockchain fork to Bitcoin could adversely affect the business.
• Due diligence procedures to mitigate transaction risk with sanctioned entities may fail.
• Inflation, monetary response, and economic impacts (e.g., interest rates, trade restrictions, climate-related events).

Future Outlook

Management expects to continue incurring substantial losses due to ongoing research and development activities. Additional funds will be necessary for successful product commercialization efforts. The Company is working towards meeting regulatory requirements in Europe for Lumee Oxygen reader commercialization in early 2026, and Lumee Glucose launch in Europe is expected in 2025, subject to regulatory approval. Additional financing is available through the sale of Common Stock via the ELOC and executing tranches three and four of the PIPE Subscription Agreement, which could provide up to an additional $10.0 million. The Company anticipates making substantial investments in building European and United States commercial infrastructure, enhancing existing products, developing new ones, and continuing discussions with potential partners in Asia for the APAC Joint Venture. Increased expenses are expected due to operating as a public company, and a combination of equity and debt financing will be utilized to fund future capital needs until sufficient operating cash flow is generated. Future capital requirements will depend on various factors including revenue growth, customer cash receipts, sales and marketing expansion, and development spending.

Management Comments

• "Management expects to continue to incur additional substantial losses in the foreseeable future as a result of research and development activities."
• "Management believes this liquidity is not sufficient to alleviate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued."
• "The Company is currently working towards meeting regulatory requirements in Europe in order to commercialize the Lumee Oxygen reader in order to generate revenues in early 2026."
• "The Company is monitoring the MVLS of its listed securities and is considering available options to regain compliance with Nasdaq’s continued listing standards."
• "The Company is monitoring the minimum bid price of its listed securities and is considering available options to regain compliance with Nasdaq’s continued listing standards."
• "We expect our research and development expenses to increase as we increase staffing to support product development, continue our clinical trials, build prototypes, and continue to explore and develop next generation technologies."
• "It is our expectation to continue to make substantial investments in building its European and United States commercial infrastructure and enhancing existing products and developing new ones."
• "We expect to incur additional expenses due to operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and those of the Nasdaq Stock Market LLC, additional insurance expenses, investor relations activities and other administrative, professional and consulting services."
• "The Company plans to remediate such weaknesses [in internal controls]."
• "In connection with the Business Combination, the Company hired a new CFO with significant experience, including financial reporting and internal controls."

Industry Context

The company operates in the digital health and medical technology industry, specifically focusing on biointegrated sensors for continuous monitoring (e.g., oxygen, glucose). This is a growing sector driven by demand for personalized health data and chronic disease management. The Lumee Oxygen Platform targets critical limb ischemia and chronic wounds, areas with significant unmet medical needs. The Lumee Glucose Platform aims to compete in the continuous glucose monitoring (CGM) market, offering a potentially less invasive, longer-term solution compared to existing finger-stick or weekly sensor replacement methods. This market is highly competitive with established players but also has high growth potential due to the increasing prevalence of diabetes. The company's strategy to target both direct-to-hospital and direct-to-pharmacy sales for Lumee Glucose, and seeking CPT codes, indicates an awareness of market access and reimbursement challenges in the medical device industry. The adoption of a Bitcoin treasury strategy is unusual for a clinical-stage medical technology company and introduces significant exposure to the volatile digital asset market, diverging from typical corporate treasury management practices in the industry. This strategy reflects a high-risk, high-reward approach to liquidity management.

Comparison to Industry Standards

• The company's significant net losses and negative operating cash flows are typical for a clinical-stage biotech/medtech company heavily invested in R&D prior to widespread commercialization.
• The Nasdaq delisting notices for MVLS and bid price are below industry standards for listed companies and indicate significant market underperformance or lack of investor confidence.
• The identified material weaknesses in internal controls are below the expected standards for a public company, especially post-merger.
• The Bitcoin treasury strategy is not a standard practice for medical technology companies and introduces a unique risk profile compared to industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• To the knowledge of management, there is no litigation currently pending or contemplated against the company, its officers or directors in their capacity as such, or against any of its property.

Related Party Transactions

• Tasly (Shareholder): Convertible debt payable at fair value of $2.207 million as of September 30, 2025.
• Ascent (Shareholder): PIPE convertible note and Loan payable related party at fair value of $14.359 million as of September 30, 2025.
• Northview Acquisition Corp Sponsor (Shareholder): Convertible debt payable at fair value of $1.920 million as of September 30, 2025, and Due to related party of $41 thousand.
• The founders (Shareholder): Promissory notes of $878 thousand as of September 30, 2025.
• Various Individuals (Shareholder): Convertible debt payable of $0 as of September 30, 2025 (converted from $22.822 million at Dec 31, 2024).
• Nonrecourse promissory note to an executive for early exercised stock options ($428 thousand) was settled upon the Business Combination.

Stakeholder Impact

• Shareholders: Significant dilution risk from ELOC and PIPE conversions, potential delisting from Nasdaq, increased volatility due to Bitcoin treasury strategy, and substantial ongoing losses impacting shareholder value.
• Employees: Stock-based compensation is a component of overall compensation, but the company's going concern doubt and financial instability could impact job security and future equity value.
• Customers: Potential for new products (Lumee Oxygen, Lumee Glucose) to improve health outcomes, but commercialization delays or financial instability could affect product availability and support.
• Suppliers/Creditors: Default on PPP Loan and promissory notes indicates payment risk. The company's financial health could impact its ability to meet obligations.
• Regulatory Authorities: Nasdaq delisting notices and identified material weaknesses in internal controls indicate areas of concern for regulatory compliance.

Next Steps

• Regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) (minimum MVLS of $50,000,000) by March 10, 2026.
• Regain compliance with Nasdaq Listing Rule 5450(a)(1) (minimum bid price of $1.00 per share) by March 10, 2026.
• Continue research and development activities for Lumee Oxygen and Lumee Glucose platforms.
• Meet regulatory requirements in Europe for Lumee Oxygen commercialization in early 2026.
• Seek regulatory approval for Lumee Glucose launch in Europe in 2025.
• Continue to fund operating cash flows through the Committed Equity Facility (ELOC).
• Work towards meeting conditions for Tranches three and four of the PIPE Subscription Agreement to secure an additional $10.0 million.
• Apply for forgiveness for PPP Loan 2 prior to December 31, 2025.
• Continue discussions with potential partners in Asia for the APAC Joint Venture.
• Remediate identified material weaknesses in internal control over financial reporting.
• Draft and implement a new 2025 Equity Incentive Plan.
• Monitor and potentially adjust the Bitcoin treasury strategy.

Key Dates

Recommendation

The company is in a precarious financial position, marked by rapidly escalating net losses, negative operating cash flow, and an explicit "going concern" warning from management. The Nasdaq delisting notices for both market value and bid price indicate severe market underperformance and a high risk of losing its exchange listing, which would significantly impair liquidity and investor confidence. While the business combination and ELOC provide some capital, the magnitude of losses and the working capital deficit suggest these funds may be insufficient to achieve sustainable operations. The adoption of a Bitcoin treasury strategy introduces an additional layer of extreme volatility and risk, which is highly unusual for a clinical-stage medical technology company and further complicates its financial outlook. Material weaknesses in internal controls also raise concerns about financial reporting reliability. Given these overwhelming negative factors and the high probability of further value erosion, a strong sell recommendation is warranted.

Keywords

Biointegrated Sensors, Continuous Glucose Monitoring, Lumee Oxygen Platform, Lumee Glucose Platform, SEC Filing, 10-Q, Financial Results, Net Loss, Going Concern, Nasdaq Delisting, Bitcoin Treasury Strategy, Digital Assets, Equity Line of Credit, PIPE Investment, Medical Technology, Digital Health, Clinical Stage, R&D Expenses, Corporate Governance, Internal Controls, Reverse Recapitalization